Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction.
No significant differences in CD34⁺ mobilization, apheresis outcomes, engraftment, or early post-autologous hematopoietic stem cell transplantation complications were observed based on prior daratumumab exposure, supporting the safety and feasibility of autologous hematopoietic stem cell transplantation following anti-...